sees fy adjusted earnings per share $num-one to $num - two from continuing operations.
sees fy adjusted net earnings per diluted share $num-one to $2.00 excluding items.
sees year-six organic net sales growth to be in range of num-one% to num-two%.
qtr-three earnings per share $num-one.
qtr-four adjusted earnings per share $num-one.
qtrly organic sales growth of num-one%.
qtrly international organic growth of num-one%, led by strong growth in europe, australia, canada and emerging markets.
qtrly international sales declined num-one% compared to prior year.
qtr-three adjusted earnings per share $num-one.
qtrly adjusted gross margin of num-one% was favorable about num-two basis points from year-four.
qtrly international organic sales increased num-one% to $num-one billion.
cash from operations for qtr-one of year-six was $num-one billion.
qtrly endoscopy sales increased num-one% on an organic basis.
qtrly organic sales growth of num-three%.
qtrly adjusted r&d spending of $num-one billion, or num-one% of sales, was driven by continued focus on innovation.
expect net sales in full year year-six to be positively impacted by approximately num-one% of foreign currency exchange rates.
